Vascular histone deacetylation by pharmacological HDAC inhibition

Genome Research

Volumn 24, Issue 8, 2014, Pages 1271-1284

  Rafehi, Haloom ^a,b   Balcerczyk, Aneta ^a,d   Lunke, Sebastian ^a,b   Kaspi, Antony ^a   Ziemann, Mark ^a   Harikrishnan, K N ^a   Okabe, Jun ^a,c   Khurana, Ishant ^a   Ooi, Jenny ^a   Khan, Abdul Waheed ^a   Du, Xiao Jun ^a,c   Chang, Lisa ^a   Haviv, Izhak ^a,d   Keating, Samuel T ^a   Karagiannis, Tom C ^a   El Osta, Assam ^a,b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE H3; INTERLEUKIN 6; INTERLEUKIN 8; LYSINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEAR RECEPTOR COACTIVATOR; NUCLEAR RECEPTOR COACTIVATOR 2; STROMELYSIN 2; TRICHOSTATIN A; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VORINOSTAT; ANTIINFLAMMATORY AGENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PROTEIN BINDING; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DEACETYLATION; DNA METHYLATION; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEART FUNCTION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RNA SEQUENCE; TRANSCRIPTION INITIATION SITE; VASCULAR ENDOTHELIUM; ACETYLATION; ANIMAL; AORTA; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; HUMAN GENOME; METABOLISM; PROTEIN PROCESSING;

ACETYLATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENOME, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84905654622     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.168781.113     Document Type: Article

References (65)

1. Albaugh BN, Arnold KM, Lee S, Denu JM. 2011. Autoacetylation of the histone acetyltransferase Rtt109. J Biol Chem 286: 24694-24701.
2. Almeida AM, Murakami Y, Baker A, Maeda Y, Roberts IA, Kinoshita T, Layton DM, Karadimitris A. 2007. Targeted therapy for inherited GPI deficiency. N Engl J Med 356: 1641-1647. (Pubitemid 46631673)
3. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57: 289-300.
4. Blanchette M, Bataille AR, Chen X, Poitras C, Laganiere J, Lefebvre C, Deblois G, Giguere V, Ferretti V, Bergeron D, et al. 2006. Genome-wide computational prediction of transcriptional regulatory modules reveals new insights into human gene expression. Genome Res 16: 656-668.
5. Blanco-Garcia N, Asensio-Juan E, de la Cruz X, Martinez-Balbas MA. 2009. Autoacetylation regulates P/CAF nuclear localization. J Biol Chem 284: 1343-1352.
6. Bolden JE, Peart MJ, Johnstone RW. 2006. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. (Pubitemid 44348499)
7. Bush EW, McKinsey TA. 2010. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 106: 272-284.
8. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. 2006. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126: 321-334. (Pubitemid 44092958)
9. Chang L, Kiriazis H, Gao XM, Du XJ, El-Osta A. 2011. Cardiac genes show contextual SWI/SNF interactions with distinguishable gene activities. Epigenetics 6: 760-768.
10. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840.
11. Coulson JM. 2005. Transcriptional regulation: cancer, neurons and the REST. Curr Biol 15: R665-668. (Pubitemid 41219582)
12. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. 2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749. (Pubitemid 36399066)
13. Dokmanovic M, Clarke C, Marks PA. 2007. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989. (Pubitemid 350080267)
14. Eckner R, Yao TP, Oldread E, Livingston DM. 1996. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev 10: 2478-2490. (Pubitemid 26341882)
15. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, Li YH, Wang LL, Yu L. 2013. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS ONE 8: e55481.
16. Gregoretti IV, Lee YM, Goodson HV. 2004. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31. (Pubitemid 38429783)
17. Haberland M, Montgomery RL, Olson EN. 2009. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
18. Hansson ML, Popko-Scibor AE, Saint Just Ribeiro M, Dancy BM, Lindberg MJ, Cole PA, Wallberg AE. 2009. The transcriptional coactivator MAML1 regulates p300 autoacetylation and HAT activity. Nucleic Acids Res 37: 2996-3006.
19. Hirase T, Node K. 2012. Endothelial dysfunction as a cellular mechanism for vascular failure. Am J Physiol Heart Circ Physiol 302: H499-H505.
20. Jain S, Wei J, Mitrani LR, Bishopric NH. 2012. Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival. Breast Cancer Res Treat 135: 103-114.
21. Karlic R, Chung HR, Lasserre J, Vlahovicek K, Vingron M. 2010. Histone modification levels are predictive for gene expression. Proc Natl Acad Sci 107: 2926-2931.
22. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, et al. 2006. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113: 51-59. (Pubitemid 43958488)
23. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. 2002. The human genome browser at UCSC. Genome Res 12: 996-1006. (Pubitemid 34662293)
24. Kim SH, Kang HJ, Na H, Lee MO. 2010. Trichostatin A enhances acetylation as well as protein stability of ERα through induction of p300 protein. Breast Cancer Res 12: R22.
25. Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA. 2003. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112: 863-871. (Pubitemid 38063744)
26. Kuo MH, Allis CD. 1998. Roles of histone acetyltransferases and deacetylases in gene regulation. BioEssays 20: 615-626. (Pubitemid 28422221)
27. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, Sternglanz R. 2000. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci 97: 5807-5811. (Pubitemid 30367480)
28. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, et al. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366: 549-555. (Pubitemid 41140329)
29. Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595.
30. Li Q, Herrler M, Landsberger N, Kaludov N, Ogryzko VV, Nakatani Y, Wolffe AP. 1998. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J 17: 6300-6315. (Pubitemid 28497802)
31. Li Q, Imhof A, Collingwood TN, Urnov FD, Wolffe AP. 1999. p300 stimulates transcription instigated by ligand-bound thyroid hormone receptor at a step subsequent to chromatin disruption. EMBO J 18: 5634-5652. (Pubitemid 29486382)
32. Lin Q, Schwarz J, Bucana C, Olson EN. 1997. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276: 1404-1407. (Pubitemid 27235406)
33. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R, Cole PA. 2008. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451: 846-850. (Pubitemid 351253165)
34. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. 2007. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252. (Pubitemid 350106355)
35. Margariti A, Zampetaki A, Xiao Q, Zhou B, Karamariti E, Martin D, Yin X, Mayr M, Li H, Zhang Z, et al. 2010. Histone deacetylase 7 controls endothelial cell growth through modulation of β-catenin. Circ Res 106: 1202-1211.
36. Margueron R, Reinberg D. 2011. The Polycomb complex PRC2 and its mark in life. Nature 469: 343-349.
37. Marks PA. 2010. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 1799: 717-725.
38. Marks PA, Breslow R. 2007. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90. (Pubitemid 46087907)
39. Marks PA, Xu WS. 2009. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608.
40. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim TK, Koche RP, et al. 2007. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448: 553-560. (Pubitemid 47206934)
41. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51. (Pubitemid 43054973)
42. Montgomery ND, Yee D, Chen A, Kalantry S, Chamberlain SJ, Otte AP, Magnuson T. 2005. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol 15: 942-947. (Pubitemid 40772064)
43. Nakagawa Y, Kuwahara K, Harada M, Takahashi N, Yasuno S, Adachi Y, Kawakami R, Nakanishi M, Tanimoto K, Usami S, et al. 2006. Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes. J Mol Cell Cardiol 41: 1010-1022. (Pubitemid 44802867)
44. Olson EN, Backs J, McKinsey TA. 2006. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp 274: 3-12.
45. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW. 2005. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci 102: 3697-3702. (Pubitemid 40354674)
46. Pober JS, Sessa WC. 2007. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 7: 803-815. (Pubitemid 47480307)
47. Rada-Iglesias A, Enroth S, Ameur A, Koch CM, Clelland GK, Respuela-Alonso P, Wilcox S, Dovey OM, Ellis PD, Langford CF, et al. 2007. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 17: 708-719. (Pubitemid 46919708)
48. Raney BJ, Cline MS, Rosenbloom KR, Dreszer TR, Learned K, Barber GP, Meyer LR, Sloan CA, Malladi VS, Roskin KM, et al. 2011. ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res 39: D871-D875.
49. Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estecio MR, Issa JP. 2012. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 72: 1170-1181.
50. Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139-140.
51. Roth SY, Denu JM, Allis CD. 2001. Histone acetyltransferases. Annu Rev Biochem 70: 81-120. (Pubitemid 32662206)
52. Sheridan PL, Mayall TP, Verdin E, Jones KA. 1997. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 11: 3327-3340. (Pubitemid 28023957)
53. Smith BC, Denu JM. 2009. Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 1789: 45-57.
54. Song K, Backs J, McAnally J, Qi X, Gerard RD, Richardson JA, Hill JA, Bassel-Duby R, Olson EN. 2006. The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 125: 453-466.
55. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550. (Pubitemid 41528093)
56. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149.
57. Tanner KG, Landry J, Sternglanz R, Denu JM. 2000. Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci 97: 14178-14182. (Pubitemid 32016550)
58. Thaler F, Minucci S. 2011. Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? Expert Opin Drug Discov 6: 393-404.
59. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. 2009. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138: 1019-1031.
60. Yang C, Wu J, Sinha SH, Neveu JM, Zheng YG. 2012a. Autoacetylation of the MYST lysine acetyltransferase MOF protein. J Biol Chem 287: 34917-34926.
61. Yang C, Wu J, Zheng YG. 2012b. Function of the active site lysine autoacetylation in Tip60 catalysis. PLoS ONE 7: e32886.
62. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93: 361-372. (Pubitemid 28232081)
63. Yao YL, Yang WM, Seto E. 2001. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol 21: 5979-5991. (Pubitemid 32737814)
64. Yoshida M, Kijima M, Akita M, Beppu T. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179.
65. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, et al. 2008. Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137.